# Andreas Stallmach

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andreas-stallmach/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,528 |
| Field | Inflammatory Bowel Disease |
| h-index | 65 |
| i10-index | 290 |
| Last Known Institution | Klinikum Magdeburg |
| OpenAlex ID | https://openalex.org/A5078081528 |
| ORCID iD | 0000-0002-6101-5244 |
| Works | 912 |

## Researcher papers

Showing 12 of 13.

- [NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression](https://scholariq.org/papers/nod2-card15-mutations-in-crohn-s-disease-are-associated-with-diminished-mucosal/)
- [Peripheral and Intestinal Regulatory CD4+CD25high T Cells in Inflammatory Bowel Disease](https://scholariq.org/papers/peripheral-and-intestinal-regulatory-cd4-cd25high-t-cells-in-inflammatory-bowel/)
- [Effects of Antibiotics on Gut Microbiota](https://scholariq.org/papers/effects-of-antibiotics-on-gut-microbiota/)
- [TGF-β and fibrosis in different organs — molecular pathway imprints](https://scholariq.org/papers/tgf-and-fibrosis-in-different-organs-molecular-pathway-imprints/)
- [Drug delivery strategies in the therapy of inflammatory bowel disease](https://scholariq.org/papers/drug-delivery-strategies-in-the-therapy-of-inflammatory-bowel-disease/)
- [Expression of Interleukin-12-Related Cytokine Transcripts in Inflammatory Bowel Disease: Elevated Interleukin-23p19 and Interleukin-27p28 in Crohnʼs Disease But Not in Ulcerative Colitis](https://scholariq.org/papers/expression-of-interleukin-12-related-cytokine-transcripts-in-inflammatory-bowel/)
- [Adverse effects of biologics used for treating IBD](https://scholariq.org/papers/adverse-effects-of-biologics-used-for-treating-ibd/)
- [Use of Intestinal Ultrasound to Monitor Crohn’s Disease Activity](https://scholariq.org/papers/use-of-intestinal-ultrasound-to-monitor-crohn-s-disease-activity/)
- [Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial](https://scholariq.org/papers/guselkumab-plus-golimumab-combination-therapy-versus-guselkumab-or-golimumab/)
- [A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease](https://scholariq.org/papers/a-randomized-trial-of-a-transglutaminase-2-inhibitor-for-celiac-disease/)
- [S1-Leitlinie Post-COVID/Long-COVID](https://scholariq.org/papers/s1-leitlinie-post-covid-long-covid/)
- [Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study](https://scholariq.org/papers/vedolizumab-provides-clinical-benefit-over-1-year-in-patients-with-active/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Clostridium difficile and Clostridium perfringens research](https://scholariq.org/topics/clostridium-difficile-and-clostridium-perfringens-research/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)

## Researcher university

- [Klinikum Magdeburg](https://scholariq.org/institutions/klinikum-magdeburg/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.